132 related articles for article (PubMed ID: 1441599)
1. Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9).
Kato R; Yamazoe Y; Yasumori T
Xenobiotica; 1992; 22(9-10):1083-92. PubMed ID: 1441599
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.
Yasumori T; Murayama N; Yamazoe Y; Kato R
Clin Pharmacol Ther; 1990 Mar; 47(3):313-22. PubMed ID: 2311333
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and polymorphism of human P-450 which activates and detoxicates xenobiotics and carcinogens.
Kato R; Yamazoe Y; Yasumori T
Princess Takamatsu Symp; 1990; 21():45-53. PubMed ID: 2134689
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts.
Yasumori T; Yamazoe Y; Kato R
J Biochem; 1991 May; 109(5):711-7. PubMed ID: 1917894
[TBL] [Abstract][Full Text] [Related]
5. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae.
Brian WR; Srivastava PK; Umbenhauer DR; Lloyd RS; Guengerich FP
Biochemistry; 1989 Jun; 28(12):4993-9. PubMed ID: 2669966
[TBL] [Abstract][Full Text] [Related]
6. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
8. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects.
Adedoyin A; Prakash C; O'Shea D; Blair IA; Wilkinson GR
Pharmacogenetics; 1994 Feb; 4(1):27-38. PubMed ID: 8004130
[TBL] [Abstract][Full Text] [Related]
11. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.
Shimada T; Misono KS; Guengerich FP
J Biol Chem; 1986 Jan; 261(2):909-21. PubMed ID: 3079764
[TBL] [Abstract][Full Text] [Related]
12. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.
Srivastava PK; Yun CH; Beaune PH; Ged C; Guengerich FP
Mol Pharmacol; 1991 Jul; 40(1):69-79. PubMed ID: 1857342
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.
Meier UT; Meyer UA
Biochemistry; 1987 Dec; 26(25):8466-74. PubMed ID: 3442670
[TBL] [Abstract][Full Text] [Related]
14. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
Kobayashi K; Kogo M; Tani M; Shimada N; Ishizaki T; Numazawa S; Yoshida T; Yamamoto T; Kuroiwa Y; Chiba K
Drug Metab Dispos; 2001 Jan; 29(1):36-40. PubMed ID: 11124227
[TBL] [Abstract][Full Text] [Related]
15. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
Tybring G; Bertilsson L
Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
17. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.
Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI
Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777
[TBL] [Abstract][Full Text] [Related]
18. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16 alpha-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin.
Shimada T; Guengerich FP
Mol Pharmacol; 1985 Aug; 28(2):215-9. PubMed ID: 4022003
[TBL] [Abstract][Full Text] [Related]
19. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
[TBL] [Abstract][Full Text] [Related]
20. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
